Peroxynitrite in reperfusion arrhythmias and its whole blood chemiluminescence results.
The aims of the present study were to investigate the effects of exogenous peroxynitrite (ONOO(-)) on reperfusion arrhythmias in anaesthetized rats, and to detect endogenous and exogenous ONOO(-)-induced chemiluminescence (CL) signals in rat whole blood, which was collected during baseline and in the first minute of reperfusion. ONOO(-) infusion in ischemia/reperfusion (I/R) applied groups caused significant decreases in mean arterial pressure (MAP) and heart rate (HR). Ventricular fibrillation (VF) incidences in the vehicle, ONOO(-), and dec-ONOO(-) infused groups were 63, 100, and 20%, respectively. In control group CL signal was 136+/-34mV during the resting period and was increased to 336+/-57mV with reperfusion. Also, the effects of SOD+CAT, L-NAME and urate were investigated. Ventricular tachycardia (VT) incidence was decreased significantly in SOD+CAT and urate; VF incidence was decreased significantly in SOD+CAT applied groups. CL signals were inhibited with SOD+CAT, L-NAME, and urate. Exogenous ONOO(-) infusion during I/R was also investigated. CL signal in exogenously ONOO(-) infused group is increased 423% during reperfusion. Only urate infused group VF incidence was decreased significantly. CL signals of ONOO(-) infused groups were inhibited by SOD+CAT, L-NAME, and urate. Based on the results of the current study, ONOO(-) seems to be one of the key mediators of reperfusion arrhythmias in anaesthetized rats.
Department of Pharmacology, Baskent University, School of Medicine, Eskisehir Road 20.Km, Baglica Campus, 06530 Ankara, Turkey. mtunal@baskent.edu.tr
Müge
M
Tecder-Unal
Ylker
Y
Kanzýk
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002374:Catalase / Q000494:pharmacology / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D007262:Infusions, Intravenous; D008163:Luminescent Measurements; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D030421:Peroxynitrous Acid / Q000097:blood / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000494:pharmacology / Q000627:therapeutic use; D017180:Tachycardia, Ventricular / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D014527:Uric Acid / Q000494:pharmacology / Q000627:therapeutic use; D014693:Ventricular Fibrillation / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D014785:Vision, Ocular / Q000187:drug effects
D004791:Enzyme Inhibitors; D016166:Free Radical Scavengers; D017382:Reactive Oxygen Species; D030421:Peroxynitrous Acid; D014527:Uric Acid; D009240:N-Formylmethionine Leucyl-Phenylalanine; D002374:Catalase; D013482:Superoxide Dismutase; D019331:NG-Nitroarginine Methyl Ester